Healthcare Industry News: Sosei
News Release - October 4, 2007
Declan P. Doogan, M.D. Joins IRX Therapeutics as Advisor on Global Product DevelopmentNEW YORK--(HSMN NewsFeed)--IRX Therapeutics, a privately-held company dedicated to the development and commercialization of novel drugs for the treatment of cancer and viral diseases, today announced that Declan P. Doogan, M.D., FRCP (Glas), FFPM, DSc has joined the Company as an advisor on global product development and strategic partnering.
Dr. Doogan, a global leader in drug development, was Senior Vice President Global Research and Development and Head of Worldwide Development at Pfizer, Inc. Dr. Doogan joined Pfizer in 1982, where he led the Zoloft® clinical development program and held a number of senior positions in the U.S., Japan and U.K. Dr. Doogan is currently the President of Research and Development at Amarin Corporation plc, focused on improving the lives of patients suffering from diseases of the central nervous system, a position he will retain.
"We are pleased to welcome Dr. Doogan to our team," said John W. Hadden, II, President & Chief Executive Officer. "Dr. Doogan has an outstanding track record and his experience in drug development will be extremely valuable as we move toward a pivotal Phase 3 global clinical trial of our lead therapeutic IRX-2."
In addition to Dr. Doogan's work at Amarin, he holds Visiting Professorships in Drug Development Science at Glasgow University Medical School, U.K., Harvard University School of Public Health, U.S., and Kitasato University Tokyo, Japan. Dr. Doogan's Board of Director memberships include the Sosei Corporation, a global biopharmaceutical company, and Alimentary Health Limited, a company focused on the isolation, characterization and clinical evaluation of probiotic bacteria in inflammatory and infectious conditions. Dr. Doogan received his medical degree from Glasgow University and is a Fellow of the Royal College of Physicians of Glasgow and the Faculty of Pharmaceutical Medicine in the U.K.
"I am excited to join IRX Therapeutics as it continues the development of IRX-2 and looks to expand and develop other cancer and viral products," said Dr. Doogan. "The company's work on immunotherapeutic treatments for head and neck cancer could be applicable to other cancers."
IRX Therapeutics discovers and develops therapeutic treatments that act on multiple cellular targets to restore the immune system's ability to treat cancer and viral diseases. IRX-2 seeks to correct both dendritic cell and T-cell defects to stimulate an immune response to destroy tumor cells. IRX-2 received Fast Track designation by the Food and Drug Administration in November of 2003. An open label Phase 2 clinical trial in late-stage head and neck cancer patients was completed which demonstrated statistically significant improvement in the treatment group and a clinical response rate of 38%. After forty-eight months, the overall survival of IRX-2 treated patients was 61% versus 32% for the concurrent institutional control group.
About IRX Therapeutics
IRX Therapeutics is a privately held immunotherapy company focusing on the development and commercialization of treatments for advanced cancer and viral diseases. Founded in 1994 by John W. Hadden, M.D., a pioneer in the field of Immunopharmacology, IRX Therapeutics is developing an innovative approach that stimulates a coordinated cellular immune response to treat human diseases. The Company's product pipeline includes IRX-2, a therapeutic cancer therapy that seeks to stimulate a cellular immune response in the host to destroy tumor cells. Other products in development similarly seek to stimulate a cellular immune response for the treatment of other cancers and viral diseases. This immune response is essential for the eradication of most viruses and tumors, and relies on the effective functioning of dendritic cells, macrophages, and T-cells.
For more information on IRX Therapeutics, please visit the Company's website at http://www.irxtherapeutics.com.
Source: IRX Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.